text.skipToContent text.skipToNavigation

What are pyrogens and endotoxins?

Pyrogens are fever-inducing substances primarily derived from microorganisms such as bacteria, viruses, yeasts, molds, or chemical substances, e.g. primary packaging materials. Pyrogens entering the bloodstream may interact with the host immune system to cause inflammation, fever, chills, shock and, in severe cases, death.

Pyrogens include membrane-derived compounds like lipid-polysaccharides (LPS), flagellin, peptidoglycans, lipids, proteins, etc. They are often heat stable and therefore difficult to remove during manufacturing. The most potent type of pyrogens are bacterial endotoxins which are derived from the cell wall of gram-negative bacteria. Pyrogens that derive from microorganisms other than gram-negative bacterial are collectively referred to as non-endotoxin pyrogens (NEPs).

There are a variety of methods that can be used to detect pyrogens: The traditional qualitative approach has been the rabbit pyrogen test (RPT), which involves measuring the body temperature increase in rabbits following injection of a product potentially containing pyrogens. The monocyte activation test (MAT) was introduced as a sustainable, in vitro alternative to the use of experimental animals. The MAT is based on measuring the release of pro-inflammatory cytokines from cultured human blood monocytes in response to pyrogenic contaminants. MAT kits, such as the PyroCell® MAT System, which measure release of IL-6 are especially useful early in drug development when the presence of all pyrogens should be examined, and testing is not focused specifically on endotoxins.

Bacterial endotoxins are the most potent pyrogenic contaminants and are ubiquitous. Thus, we must try to keep the endotoxin levels as low as possible for all injectable drugs and implantable medical devices. The bacterial endotoxins test (BET) has widely replaced the RPT for pharmaceutical and biotechnology products. Traditional BET using Limulus amebocyte lysate (LAL) tests contain specialized blue blood cells from the wild Atlantic horseshoe crab, Limulus polyphemus, as a component because they react to the presence of endotoxins in a way that can be measured and quantitated. (Similarly, tests available in Asia include cells from an Asian horseshoe crab species, Tachypleus spp., and are called TAL assays.) Sustainable tests, using a recombinant version of the first enzyme in the LAL clotting cascade, such as the PyroGene® rFC Assay, do not rely on the blood of horseshoe crabs. The use of an alternative method reduces the demand on a natural resource and can help meet supply chain sustainability initiatives. They are gaining usage across the globe as companies seek to reduce their reliance on natural resources.


Monocyte Activation Test

With PyroCell® Monocyte Activation Tests (MAT) we can eliminate the reliance on rabbit-based pyrogen testing, helping to ensure drug product safety and compliance. 

Learn about MAT

Run assays with the right reader

Learn about conducting traditional kinetic LAL Assays and recombinant Factor C technology in one easy-to-use instrument. Find out more about Lonza's Nebula® Readers. 

Nebula® Readers

Automation in the testing lab

Implementing the PyroTec® PRO Automated Robotic Solution can reduce the potential for human error and enhance the accuracy, reliability and traceability of results. 

PyroTec® PRO

Learn in the QC Insider® Toolbox

The QC Insider® Toolbox is a vast library of tech tips, white papers, and e-learning modules designed to help you with your pyrogen and endotoxin testing program.

Become a QC Insider®

Topics in endotoxin testing

BET and test types


The bacterial endotoxin test (BET) is a critical part of quality control (QC) testing. Testing products for the presence of bacterial endotoxins is a fundamental safety requirement in the pharmaceutical and biomedical industries and is performed on raw and in-process materials and for the final release of injectable or implantable products. These QC tests must comply with regulatory requirements enforced by global regulatory agencies.

The Limulus amebocyte lysate (LAL) assay was first developed in the 1960s and commercialized as a BET in the U.S. in the 1970s. The LAL assay is formulated using specialized blood cells, or amebocytes, obtained from the blue blood of Atlantic horseshoe crabs. The amebocytes function as the crab’s only immune defense: a blood coagulation system. After encountering foreign substances including endotoxin, amebocytes generate clots that immobilize and kill the pathogens.

Even minimal amounts of endotoxin, less than a billionth of a gram, can trigger this immune response. This occurs via a complex clotting cascade, which has been extensively investigated since the LAL assay was first developed.

The first enzyme in this cascade is the Factor C (FC) enzyme (the biosensor), which binds to the hydrophobic Lipid A component of the LPS molecule to initiate a cascade of enzymatic reactions that result in the formation of a blood clot. LAL testing takes advantage of this endotoxin-sensitive clotting response to produce a BET assay that is reliable, sensitive and specific.

As LAL testing relies on harvesting the blood of wild horseshoe crabs, the conservation of horseshoe crab populations is a key priority. In the U.S., a variety of conservation initiatives have been widely successful in ensuring sustainable harvesting practices. However, the situation is more serious in Asia, where unsustainable blood harvesting practices for TAL production are causing serious population declines.

These considerations have contributed to the development of alternative BET methods that do not rely on harvested crab blood such as the recombinant Factor C (rFC) assay. These assays utilize a cloned version of the Factor C enzyme. When activated in the presence of endotoxin, Factor C cleaves a fluorescent substrate creating a signal that is measured in the rFC assay.

In total, four main types of BET methods have been developed based on the principles of LAL testing. They all have important applications in QC testing during the manufacture of parenteral medicines and injectable devices.

Test types

Description Test type

Qualitative tests


Simple yes / no answer

Gel Clot Assay

This is a simple LAL test with visual inspection of gel formation. This does not require an incubating reader and software to complete.

More details

Quantitative tests


Reveals not only the presence of endotoxin, but also the amount present. Results are calculated from a standard curve.

Turbidimetric LAL Assay

Kinetic measurement of turbidity development is a cost-effective way of BET testing water samples or large volume parenterals.

More details

Chromogenic LAL Assay

Kinetic measurement of color development allows a quantitative readout of the endotoxin concentration in the sample measured.

More details

Recombinant Factor C Assay

Sustainably synthesized alternative to LAL assays based on the recombinantly produced form of Factor C. Does not rely on horseshoe crab blood.

More details

Lonza offers semi-qualitative tests that measure gel clot formation, such as the PYROGENT® Gel Clot Assay, and quantitative tests that measure turbidity with the PYROGENT® 5000 Kinetic Turbidimetric Assay, a color change with the Kinetic-QCL® Kinetic Chromogenic LAL Assay or a fluorescence change with the sustainable PyroGene® rFC Assay.

All of our quantitative tests are developed and optimized for use with the WinKQCL® Endotoxin Detection Software and our incubating microplate readers. Further, all of our quantitative assays can be automated with our PyroTec® PRO Automated Endotoxin Testing System.

 

Quantitative methods rely on the combination of test kits, validated instruments and software that provides data integrity. Download our Complete Testing Solutions e-book to learn about all of the kits, components, instruments and software that Lonza provides to meet all of your testing needs.

What is low endotoxin recovery (LER)?


Low Endotoxin Recovery (LER) is a controversial topic that has been circulating throughout the endotoxin detection community since 2013. This phenomenon is hypothetically described as a “masking effect” manifested in the biophysical formation of a complex that blocks the ability of Factor C, the main component in LAL detection, to bind endotoxin.

Two common drug excipients, polysorbate and citrate, have been identified as probable causes of the masking effect more commonly referred to as LER. These substances are estimated to be used in more than 70% of protein formulations. There is also some evidence that phosphate-containing formulations may also be affected by LER. However, the LER effect has only been observed in combination formulations of the aforementioned excipients, and not in individual raw materials.

Key points

  • This 'phenomenon' has been observed for more than 20 years, but never identified
  • Underlying mechanism of action is still unknown
  • Primarily affects formulations of polysorbate/citrate buffers
  • Naturally occurring endotoxin (NOE) preparations and other 'de-masking' solutions are currently being evaluated